Roche
World's largest biotech — pioneered monoclonal antibodies with Herceptin/Rituxan; Genentech subsidiary leads oncology and personalized medicine biologics R&D.
- Country
- Switzerland
- Revenue
- CHF 58.7B
- Employees
- ~100,000 emp
GMP EU
FDA GMP
ICH Q7
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
| Diagnostics & biosensors | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.